Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide

Yoshihiro Niitsu, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Fuminori Satou, Motoyoshi Tsujino, Kazuki Ota, Atsushi Kudo, Minoru Tanabe, Tetsuya Yamada, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

抄録

Diazoxide is recognized as an effective medical treatment for insulinoma. However, due to its adverse effects, such as fluid retention, it is sometimes difficult to employ diazoxide at an effective dose in clinical practice. This study aimed to clarify the clinical factors, which may affect efficacy and safety of the diazoxide treatment. We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases. The patients were divided into two groups according to the presence or absence of favorable outcomes or adverse effects, and the clinical features of both groups were compared. Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma. Additionally, the tumor size determined by imaging test was tended to smaller than the ineffective group but not statistically significant when malignant cases were excluded (p = 0.065). Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide. In these patients, the diazoxide dose was significantly higher than that in the other patients [400 mg/day (250–500 mg/day) vs. 225 mg/day (50–425 mg/day), p = 0.027]. These findings may be informative in determining the indication and dose of diazoxide against insulinoma. In addition, a careful evaluation of platelet count would be required for a few weeks after the initiation of diazoxide treatment.

元の言語英語
ページ(範囲)149-155
ページ数7
ジャーナルEndocrine Journal
66
発行部数2
DOI
出版物ステータス出版済み - 1 1 2019
外部発表Yes

Fingerprint

Diazoxide
Insulinoma
Platelet Count
Thrombocytopenia
Medical Records
Therapeutics
Safety

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

これを引用

Niitsu, Y., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., Satou, F., ... Ogawa, Y. (2019). Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocrine Journal, 66(2), 149-155. https://doi.org/10.1507/endocrj.EJ18-0353

Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. / Niitsu, Yoshihiro; Minami, Isao; Izumiyama, Hajime; Hashimoto, Koshi; Yoshimoto, Takanobu; Satou, Fuminori; Tsujino, Motoyoshi; Ota, Kazuki; Kudo, Atsushi; Tanabe, Minoru; Yamada, Tetsuya; Ogawa, Yoshihiro.

:: Endocrine Journal, 巻 66, 番号 2, 01.01.2019, p. 149-155.

研究成果: ジャーナルへの寄稿記事

Niitsu, Y, Minami, I, Izumiyama, H, Hashimoto, K, Yoshimoto, T, Satou, F, Tsujino, M, Ota, K, Kudo, A, Tanabe, M, Yamada, T & Ogawa, Y 2019, 'Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide' Endocrine Journal, 巻. 66, 番号 2, pp. 149-155. https://doi.org/10.1507/endocrj.EJ18-0353
Niitsu Y, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Satou F その他. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocrine Journal. 2019 1 1;66(2):149-155. https://doi.org/10.1507/endocrj.EJ18-0353
Niitsu, Yoshihiro ; Minami, Isao ; Izumiyama, Hajime ; Hashimoto, Koshi ; Yoshimoto, Takanobu ; Satou, Fuminori ; Tsujino, Motoyoshi ; Ota, Kazuki ; Kudo, Atsushi ; Tanabe, Minoru ; Yamada, Tetsuya ; Ogawa, Yoshihiro. / Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. :: Endocrine Journal. 2019 ; 巻 66, 番号 2. pp. 149-155.
@article{2a2b5485c3c14473a471237155714f4f,
title = "Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide",
abstract = "Diazoxide is recognized as an effective medical treatment for insulinoma. However, due to its adverse effects, such as fluid retention, it is sometimes difficult to employ diazoxide at an effective dose in clinical practice. This study aimed to clarify the clinical factors, which may affect efficacy and safety of the diazoxide treatment. We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases. The patients were divided into two groups according to the presence or absence of favorable outcomes or adverse effects, and the clinical features of both groups were compared. Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma. Additionally, the tumor size determined by imaging test was tended to smaller than the ineffective group but not statistically significant when malignant cases were excluded (p = 0.065). Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide. In these patients, the diazoxide dose was significantly higher than that in the other patients [400 mg/day (250–500 mg/day) vs. 225 mg/day (50–425 mg/day), p = 0.027]. These findings may be informative in determining the indication and dose of diazoxide against insulinoma. In addition, a careful evaluation of platelet count would be required for a few weeks after the initiation of diazoxide treatment.",
author = "Yoshihiro Niitsu and Isao Minami and Hajime Izumiyama and Koshi Hashimoto and Takanobu Yoshimoto and Fuminori Satou and Motoyoshi Tsujino and Kazuki Ota and Atsushi Kudo and Minoru Tanabe and Tetsuya Yamada and Yoshihiro Ogawa",
year = "2019",
month = "1",
day = "1",
doi = "10.1507/endocrj.EJ18-0353",
language = "English",
volume = "66",
pages = "149--155",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide

AU - Niitsu, Yoshihiro

AU - Minami, Isao

AU - Izumiyama, Hajime

AU - Hashimoto, Koshi

AU - Yoshimoto, Takanobu

AU - Satou, Fuminori

AU - Tsujino, Motoyoshi

AU - Ota, Kazuki

AU - Kudo, Atsushi

AU - Tanabe, Minoru

AU - Yamada, Tetsuya

AU - Ogawa, Yoshihiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diazoxide is recognized as an effective medical treatment for insulinoma. However, due to its adverse effects, such as fluid retention, it is sometimes difficult to employ diazoxide at an effective dose in clinical practice. This study aimed to clarify the clinical factors, which may affect efficacy and safety of the diazoxide treatment. We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases. The patients were divided into two groups according to the presence or absence of favorable outcomes or adverse effects, and the clinical features of both groups were compared. Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma. Additionally, the tumor size determined by imaging test was tended to smaller than the ineffective group but not statistically significant when malignant cases were excluded (p = 0.065). Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide. In these patients, the diazoxide dose was significantly higher than that in the other patients [400 mg/day (250–500 mg/day) vs. 225 mg/day (50–425 mg/day), p = 0.027]. These findings may be informative in determining the indication and dose of diazoxide against insulinoma. In addition, a careful evaluation of platelet count would be required for a few weeks after the initiation of diazoxide treatment.

AB - Diazoxide is recognized as an effective medical treatment for insulinoma. However, due to its adverse effects, such as fluid retention, it is sometimes difficult to employ diazoxide at an effective dose in clinical practice. This study aimed to clarify the clinical factors, which may affect efficacy and safety of the diazoxide treatment. We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases. The patients were divided into two groups according to the presence or absence of favorable outcomes or adverse effects, and the clinical features of both groups were compared. Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma. Additionally, the tumor size determined by imaging test was tended to smaller than the ineffective group but not statistically significant when malignant cases were excluded (p = 0.065). Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide. In these patients, the diazoxide dose was significantly higher than that in the other patients [400 mg/day (250–500 mg/day) vs. 225 mg/day (50–425 mg/day), p = 0.027]. These findings may be informative in determining the indication and dose of diazoxide against insulinoma. In addition, a careful evaluation of platelet count would be required for a few weeks after the initiation of diazoxide treatment.

UR - http://www.scopus.com/inward/record.url?scp=85063516140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063516140&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ18-0353

DO - 10.1507/endocrj.EJ18-0353

M3 - Article

VL - 66

SP - 149

EP - 155

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 2

ER -